DLBCL
Clinical trials for DLBCL explained in plain language.
Never miss a new study
Get alerted when new DLBCL trials appear
Sign up with your email to follow new studies for DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers driven by MYC genes
Disease control OngoingThis study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults…
Matched conditions: DLBCL
Phase: PHASE1, PHASE2 • Sponsor: Monte Rosa Therapeutics, Inc • Aim: Disease control
Last updated May 17, 2026 05:25 UTC
-
New hope for hard-to-treat brain cancer: drug combo shows promise in early trial
Disease control OngoingThis study tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults with a rare type of brain cancer (primary CNS lymphoma) that has returned or not responded to prior therapy. The goal is to see if the combination can shrink tumors and improve survival. Partic…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated May 17, 2026 05:23 UTC
-
New hope for seniors with aggressive lymphoma: targeted drug combo tested
Disease control OngoingThis study tests whether adding polatuzumab vedotin to a standard chemotherapy regimen (R-miniCHP) can help people aged 75 and older with a type of lymphoma called DLBCL. The goal is to see if the combination improves how long patients live without their cancer getting worse. Abo…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
Immunotherapy after chemo may keep High-Risk lymphoma at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab after standard chemotherapy can help prevent relapse in people with high-risk diffuse large B-cell lymphoma. About 109 adults who achieved complete remission after initial treatment received atezolizumab as a con…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 17, 2026 05:07 UTC
-
New chemo schedule aims to help elderly lymphoma patients without harsh side effects
Disease control OngoingThis study looks at a new way of giving standard chemotherapy (R-CHOP) to older adults aged 75 and up with diffuse large B-cell lymphoma. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. About 27 participants will receive t…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New antibody drug shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests an experimental drug called epcoritamab (GEN3013) in people with several types of B-cell lymphoma that have relapsed (come back) or are refractory (did not respond to prior treatment). The main goals are to find the safest and most effective dose, monitor side ef…
Matched conditions: DLBCL
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Engineered donor cells take on Hard-to-Treat lymphomas
Disease control OngoingThis early-phase study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell lymphoma that have come back or not responded to standard therapy. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The m…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Could a Pre-Treatment drug make CAR-T therapy more effective for tough lymphomas?
Disease control TerminatedThis study tests whether adding a drug called E7777 before standard CAR-T cell therapy can help people with relapsed or hard-to-treat large B-cell lymphoma. About 30 adults will receive E7777 followed by chemotherapy and an approved CAR-T product. The goal is to find the safest d…
Matched conditions: DLBCL
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 12, 2026 13:51 UTC
-
New combo therapy targets aggressive lymphoma in 75-patient trial
Disease control OngoingThis study tests whether adding ibrutinib to standard chemotherapy (R-CHOP) helps people with a specific, aggressive type of lymphoma (ABC-DLBCL) who have a poor prognosis. About 75 adults under 65 will receive the combination for 6 cycles, then take ibrutinib alone for 18 months…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated May 07, 2026 18:39 UTC